Background
==========

The efficacy of MP29-02\* (a novel intranasal formulation of azelastine hydrochloride \[AZE\] and fluticasone propionate \[FP\] in an advanced delivery system) in providing overall nasal and ocular symptom relief vs AZE, FP or placebo (PLA) has been assessed.

Methods
=======

Six hundred and ten moderate-to-severe SAR patients (≥12 yrs) were randomized into a double-blind, PLA-controlled, 14-day, parallel-group, trial (NCT00660517) to MP29-02\*, AZE, FP or PLA nasal sprays (1 spray/nostril bd; daily dose: AZE=548μg; FP=200μg) \[[@B1]\]. Change from baseline (CFB) in reflective total of 7 symptom scores (rT7SS; AM + PM, max=42) was assessed post-hoc. CFB in rT7SS and each nasal (congestion, itching, rhinorrhea, sneezing) and ocular symptom (itching, redness, watering; max=6 each) was assessed over time.

Results
=======

Overall, MP29-02\* patients showed greater reduction in rT7SS vs FP, AZE & PLA (relative diff: 52% to FP (p=0.0013), 56% to AZE (p=0.0004)) evident from treatment day 1 vs FP (p=0.0072), AZE (p=0.0336) or PLA (p\<0.0001) and sustained for 14 days. The level of relief achieved by MP29-02\* patients on Day 2 (-5.52) was not achieved before Day 5 by FP patients or Day 8 by AZE patients. This pattern of rapid, sustained and superior symptom relief by MP29-02\* was observed for each nasal and ocular symptom, which was not the case with FP and AZE. MP29-02\* provided significantly superior nasal congestion relief than FP or AZE from Day 2; the level of congestion relief provided by MP29-02\* on Day 2 (-0.77) was not achieved before Day 6 and Day 9 for FP and AZE, respectively. MP29-02\* provided significantly superior ocular itching relief vs FP from Day 2 and vs AZE from Day 3; the ocular itch relief provided by MP29-02\* on Day 2 (-0.77) was not achieved before Day 10 for FP-patients. Similarly, the level of ocular itch relief provided by MP29-02\* on Day 3 (-1.06) was not achieved by AZE-patients before Day 11.

Conclusion
==========

The consistent and rapid effect in alleviating all nasal and ocular symptoms is unique to MP29-02\* and contributes to its superiority over AZE and FP. The time advantage over firstline therapy in achieving significant relief and sustained effect should improve patient concordance. MP29-02\* is considered a new standard of care in AR.
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